Reportlinker Adds Retinal Vein Occlusion (RVO) Therapeutics – Pipeline Assessment and Market Forecasts to 2017

NEW YORK, May 24, 2011 /PRNewswire/ — Reportlinker.com
announces that a new market research report is available in its
catalogue:

Retinal Vein Occlusion (RVO) Therapeutics – Pipeline Assessment and
Market Forecasts to 2017

http://www.reportlinker.com/p0511065/Retinal-Vein-Occlusion-RVO-Therapeutics—Pipeline-Assessment-and-Market-Forecasts-to-2017.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Discovery_and_Development

Retinal Vein Occlusion (RVO) Therapeutics – Pipeline Assessment
and Market Forecasts to 2017

Summary

GlobalData, the industry analysis specialist, has released its
new report, “Retinal Vein Occlusion (RVO) Therapeutics – Pipeline
Assessment and Market Forecasts to 2017”. The report is an
essential source of information and analysis on the global RVO
market. The report identifies the key trends shaping and driving
the global RVO market. The report also provides insights on the
prevalent competitive landscape and the emerging players expected
to significantly alter the market positioning of the current market
leaders. Most importantly, the report provides valuable insights on
the pipeline products within the global RVO sector. This report is
built using data and information sourced from proprietary
databases, primary and secondary research and in-house analysis by
GlobalData’s team of industry experts.

GlobalData valued the Retinal Vein Occlusion (RVO) therapeutics
market in 2010 at $496m, indicating a growth rate of

‘/>”/>

SOURCE